Latest News

​

October 7, 2021 

​

Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19   Read more

​

July 22, 2021 

​

Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home   Read more

​

July 16, 2021 

​

Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer   Read more

​

More

Recent Publications

​

A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19

Moench T, Botta L, Farrer B, Lickliter JD, Kang H, Park Y, Kim C, Hoke M, Brennan M, McSweeney M, Richardson Z, Whelan J, Cho JM, Lee SY, Faurot F, Hutchins J, Lai SK medRxiv Aug 2022.

​

Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its development as a potent, dose-saving inhaled therapy for COVID-19 

McSweeney M, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho J, Hickey A, Lee S, Lai SK, bioRxiv Feb 2022.

​

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy 

Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK, Advanced Drug Delivery Reviews, Feb 2021.